Jean George - 22 Jun 2021 Form 4 Insider Report for Cyteir Therapeutics, Inc.

Role
Director
Signature
/s/ Andrew Gengos, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
22 Jun 2021
Net transactions value
$0
Form type
4
Filing time
24 Jun 2021, 20:48:06 UTC
Previous filing
17 Jun 2021
Next filing
24 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CYT Common Stock Conversion of derivative security +2,444,268 2,444,268 22 Jun 2021 See Footnote F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CYT Series B Convertible Preferred Stock Conversion of derivative security -7,500,000 -100% 0 22 Jun 2021 Common Stock 2,200,187 See Footnote F1, F2
transaction CYT Series C Convertible Preferred Stock Conversion of derivative security -832,026 -100% 0 22 Jun 2021 Common Stock 244,081 See Footnote F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock converted into shares of Common Stock at a ratio of 3.4088:1 upon completion of the Issuer's initial public offering. The shares have no expiration date.
F2 Shares held by Lightstone Ventures II, L.P. and Lightstone Ventures II (A), L.P. LSV Associates II, LLC is the general partner of Lightstone Ventures II, L.P. and Lightstone Ventures II (A), L.P. The Reporting Person is a managing director of LSV Associates II, LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of her pecuniary interest therein.